GlassScriptPhysician profile
Anthony P Capati
NPI 1639662950
$2,641.79
in general payments reported to CMS, 2019-2025
19 companies · $461 in 2025
The $461 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $47.91 · 2022: $462 · 2023: $1,002 · 2024: $670 · 2025: $461.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,132.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,132.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $702.16 | 2022-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $414.91 | 2022-2024 | Verquvo, Winrevair |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $359.19 | 2021-2025 | Lifevest |
| Abbott Laboratories | $201.77 | 2022-2024 | Gallant, Aveir, Amplatzer Talisman |
| Astrazeneca Pharmaceuticals LP | $165.70 | 2023-2024 | Farxiga, Brilinta |
| Janssen Pharmaceuticals, INC | $154.09 | 2023-2024 | Xarelto |
| Medtronic, INC. | $152.58 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $76.00 | 2023-2025 | |
| Edwards Lifesciences Corporation | $70.08 | 2022-2024 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Boston Scientific Corporation | $68.52 | 2021-2022 | |
| Kiniksa Pharmaceuticals International, Plc | $62.92 | 2024 | Arcalyst |
| Kiniksa Pharmaceuticals, LTD. | $40.35 | 2022 | |
| Abiomed | $40.18 | 2025 | |
| Novartis Pharmaceuticals Corporation | $30.15 | 2022-2024 | |
| Regeneron Healthcare Solutions, INC. | $24.84 | 2025 | Evkeeza |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $21.06 | 2025 | Bexsero |
| Kestra Medical Technology Services, INC. | $19.69 | 2025 | Assure Wcd |
| Actelion Pharmaceuticals US, INC. | $19.43 | 2024 | Opsumit, Uptravi |
| Novo Nordisk INC | $18.17 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Capati listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.